Patents by Inventor Lars Röse

Lars Röse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220169736
    Abstract: The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer. Other aspects of the present invention relate to a combination comprising an anti-ILDR2 antibody and a PD-1 antagonist and the use of such combination as a medicament, as well as methods of treatment or prophylaxis of a cancer in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies as described herein. Further, the present invention relates to a kit comprising anti-ILDR2 antibodies and PD-1 antagonists and optionally one or more further pharmaceutical agents.
    Type: Application
    Filed: April 6, 2020
    Publication date: June 2, 2022
    Applicants: Bayer Aktiengesellschaft, Compugen LTD.
    Inventors: Lars RÖSE, Uwe GRITZAN, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
  • Publication number: 20220133888
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars RÖSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • Patent number: 11304946
    Abstract: The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: April 19, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Julien Lefranc, Norbert Schmees, Ulrike Röhn, Ludwig Zorn, Judith Günther, Ilona Gutcher, Lars Röse, Benjamin Bader, Detlef Stöckigt, Michael Platten
  • Patent number: 11040035
    Abstract: The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 22, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
    Inventors: Norbert Schmees, Ilona Gutcher, Horst Irlbacher, Benjamin Bader, Na Zhao, Michael Platten, Ulrike Röhn, Ludwig Zorn, Lars Röse, Detlef Stöckigt
  • Publication number: 20200369769
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 26, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars RÖSE, Uwe GRITZAN, Julia HÜTTER, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
  • Publication number: 20200299269
    Abstract: The present invention covers sulphur substituted 3-oxo-2,3-dihydropyridazine-4 carboxamide compounds of general formula (I): (I) in which R1, R2, A, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 24, 2020
    Inventors: Ludwig ZORN, Ulrike RÖHN, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200289509
    Abstract: The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2017
    Publication date: September 17, 2020
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ulrike RÖHN, Ludwig ZORN, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200283395
    Abstract: The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 10, 2020
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ulrike RÖHN, Ludwig ZORN, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200283402
    Abstract: The present invention covers 3-oxo-6-heteromyl-2-phenyl-2,3-dihydropyri-dazine-4-carboxamide compounds of general formula (I): in which R1, R2, R4, R5, R6, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 10, 2020
    Inventors: Ilona GUTCHER, Ulrike RÖHN, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200237757
    Abstract: The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 23, 2017
    Publication date: July 30, 2020
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
    Inventors: Norbert SCHMEES, Ilona GUTCHER, Horst IRLBACHER, Benjamin BADER, Na ZHAO, Michael PLATTEN, Ulrike ROEHN, Ludwig ZORN, Lars ROESE, Detlef STOECKIGT
  • Publication number: 20150119372
    Abstract: The present invention describes intrauterine use of 18-methyl-15?,16?-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1) wherein R6 and R7 are hydrogen or a methylene group, in the treatment of menorrhagia, of uterine haemorrhages in general, and an intrauterine system for said use, comprising a compound of formula 1.
    Type: Application
    Filed: April 19, 2013
    Publication date: April 30, 2015
    Inventors: Norbert Schmees, Lars Röse, Tuula Valo, Katja Prelle, Reinhard Nubbemeyer, Henriikka Korolainen, Harri Jukarainen
  • Publication number: 20150065472
    Abstract: The present invention describes intrauterine use of 18-methyl-15?,16?-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1) in contraception and gynaecological treatment, and an intrauterine system comprising compounds of formula 1.
    Type: Application
    Filed: April 19, 2013
    Publication date: March 5, 2015
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Norbert Schmees, Lars Röse, Tuula Valo, Katja Prelle, Reinhard Nubbemeyer, Henriikka Korolainen, Harri Jukarainen